Identification of Serum Biomarkers to Monitor Therapeutic Response in Intestinal-Type Gastric Cancer.

ABSTRACT: There are a limited number of clinically useful serum biomarkers to predict tumor onset or treatment response in gastric cancer (GC). For this reason, we explored the serum proteome of the gp130^Y757F murine model of intestinal-type gastric cancer (IGC). We identified 30 proteins with significantly elevated expression in early gp130^Y757F IGC and 12 proteins that were significantly elevated in late gp130^Y757F IGC compared to age- and gender-matched wild-type mice. Within these signatures, there was an overlap of 10 proteins commonly elevated in both early- and late-stage disease. These results highlight the potential to identify serum biomarkers of disease stage. Since IGC in the gp130^Y757F model can be reversed followin

SUBMITTER: Dagley LF 

PROVIDER: S-EPMC10970471 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature